Purchase Summary

In order to access content on the FENIX Marketplace, you must have an account. You will also have access to FENIX Free updates.

The price for access is $599.00.

Account Information Already have an account? Log in here

LEAVE THIS BLANK

Payment Information We accept all major credit cards

By selecting this, I agree to receive emails from fenix.group.

You will be redirected to view the full article after purchasing. You will receive your account and payment information in a confirmation email, and can be viewed at any time in your Account.
RETURN TO HOME
$599
Other

UPDATED: Finerenone US Launch Analysis

Here is a brief preview of this blast: Ahead of Bayer’s Kerendia (finerenone) investor webinar on Monday, November 15 @ 9 AM ET (view link to webcast), FENIX has conducted a follow-on launch analysis. In case you missed it, FENIX performed an early Kerendia launch and HCP website analysis in October 2021 (previous FENIX insight). Below, FENIX provides an analysis of the developing Kerendia Rx data, including a time-aligned launch comparison with other key brands to see if Kerendia’s launch is more like Entresto or Brilinta.

About The Author

Matthew Maryniak

|
President of Fenix Group International
Matthew has been a thought leader in the high-growth therapeutic areas of diabetes and cardiovascular medicine since 2006, making regular attendance at large and small CV/met scientific meetings and an architect of novel methods for assessing market opportunities. He has over a decade of experience in leading CV/met consulting engagements, is a published author in PM360 and Diabetes Technology & Therapeutics, and has been quoted in The Pink Sheet on anti-thrombotics.